DECIPHERA PHARMACEUTICALS INC. news, videos and press releases
For more news please use our advanced search feature.
DECIPHERA PHARMACEUTICALS INC. - More news...
DECIPHERA PHARMACEUTICALS INC. - More news...
- Deciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences
- Deciphera Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results
- Deciphera Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 4, 2022
- Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
- Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants
- Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
- Deciphera Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
- Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results
- Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences
- Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call and Webcast on February 8, 2022
- Deciphera Pharmaceuticals Presents Results from the INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session
- Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2022 Corporate Milestones
- Deciphera Pharmaceuticals, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference
- Deciphera Pharmaceuticals Announces Restructuring to Prioritize Clinical Development Programs and Streamline Commercial Operations
- Deciphera Receives European Commission Approval of QINLOCK® for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
- Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results
- Deciphera Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 2, 2021
- Deciphera Announces Approval of QINLOCK® in Switzerland for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
- Deciphera Presents Preclinical Data from DCC-3116 Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Deciphera Pharmaceuticals Presents New Clinical Study Results Across Pipeline at the European Society for Medical Oncology (ESMO) Congress 2021
- Deciphera Pharmaceuticals, Inc. to Present at the 19th Annual Morgan Stanley Global Healthcare Conference
- Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results
- Deciphera Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 3, 2021
- Deciphera Announces First Patient Treated in Phase 1 Study of DCC-3116 in Patients with Advanced or Metastatic Tumors with a Mutant RAS or RAF Gene
- Deciphera Pharmaceuticals Presents Data from QINLOCK® and Rebastinib Programs at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
- Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences
- Deciphera Pharmaceuticals, Inc. Announces First Quarter 2021 Financial Results
- Deciphera Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 4, 2021
- Deciphera Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
- Deciphera Pharmaceuticals, Inc. to Present at the SVB Leerink 10th Annual Global Healthcare Conference
